OSAI Biopharma

Osai Biopharma is a biotechnology company dedicated to developing first-in-class oral small molecule therapeutics that modulate selective autophagy to treat chronic inflammatory and autoimmune diseases. The company's proprietary platform focuses on restoring cellular homeostasis by targeting the Sequestosome 1 (p62) pathway, which plays a critical role in clearing damaged proteins and organelles. Its lead candidate, OSAI-101, is an oral selective autophagy inducer currently being developed for the treatment of Ulcerative Colitis and Crohn's Disease. By leveraging autophagy to resolve inflammation rather than just suppressing the immune system, Osai Biopharma aims to provide safer and more effective long-term options for patients with Inflammatory Bowel Disease. The company is headquartered in San Diego and leverages deep expertise in autophagy biology to expand its pipeline into other inflammatory indications.